PRLD 241220 2.50C (PRLD241220C2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

PRLD241220C2500

Watchlist

0.01
-0.04-80.00%

15min DelayClose Dec 20 16:00 ET

0.01High0.01Low

Intraday

5D
Daily

News

Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating
Moomoo NewsDec 12 05:31 ET · Ratings
Prelude Therapeutics (PRLD) Gets a Sell From Morgan Stanley
TipRanksDec 12 05:28 ET · Ratings
Prelude Therapeutics Analyst Ratings
BenzingaDec 11 12:22 ET · Ratings
Prelude Therapeutics Reports Promising Interim Data for PRT2527 in Relapsed/Refractory Lymphoid Malignancies, Plans Partnership for Future Development
Quiver QuantitativeDec 11 07:40 ET
Express News | Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies
ReutersDec 11 07:31 ET
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies
GlobeNewswireDec 11 07:30 ET

Comments

Teo knows

23 hours ago

$Prelude Therapeutics (PRLD.US)$ iam out ty

Trytosaveabit

Dec 11 06:39

Update

$Prelude Therapeutics (PRLD.US)$ Reuters· 5 mins ago
Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies

Jaguar8

Dec 11 06:31

NEWS

$Prelude Therapeutics (PRLD.US)$
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Wednesday, 11th December at 7:30 am
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy
• Prelude plans to seek a partner for future development of PRT2527 in hematol...

Jaguar8

Sep 13 10:47

NEWS

$Prelude Therapeutics (PRLD.US)$
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activityin patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
- 3 confirmed partial re...

Stock Region

Jul 10 10:17

Therapeutics Company Announces Major Clinical Collaboration With Merck

Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...